In This Article:
Release Date: December 03, 2024
For the complete transcript of the earnings call, please refer to the full earnings call transcript.
Positive Points
-
Victrex PLC (VTXPF) experienced a 15% volume increase in the second half of FY24 compared to the first half, with full-year volumes up by 4%.
-
The company achieved its first 1,000-ton quarter in several years during the fourth quarter.
-
Victrex PLC (VTXPF) maintained robust average selling prices (ASP) despite challenges in the chemical industry and medical destocking.
-
The company reported strong cash conversion of 114% for the year, with inventory unwinding according to plan.
-
Victrex PLC (VTXPF) has completed its major investment phase, leading to significantly lower capital expenditures in the coming years.
Negative Points
-
Medical destocking continued to impact Victrex PLC (VTXPF), resulting in a 19% decline in medical revenue.
-
Profitability was significantly affected by lower asset utilization and medical destocking, leading to a 26% decrease in underlying profit before tax.
-
The company faced a 680 basis point decline in gross margin, primarily due to lower asset utilization and inventory cost impacts.
-
Victrex PLC (VTXPF) reported a higher effective tax rate of 32.5%, influenced by non-tax deductible impairments and lower patent box eligibility.
-
Currency fluctuations posed a challenge, with an anticipated GBP7 million to GBP8 million adverse impact on PBT for FY25.
Q & A Highlights
Q: Can you provide more details on the medical destocking impact and when you expect recovery? A: Jakob Sigurdsson, CEO: Medical destocking has significantly impacted our revenue, with medical down 19% year-on-year. We anticipate recovery in FY25 as demand normalizes, supported by increasing surgery rates and industry forecasts predicting a 7% revenue CAGR for medical device companies through 2030.
Q: How has the company's financial position improved, and what are the expectations for CapEx? A: Ian Melling, CFO: We have a strong financial position with a cash conversion of 114% and have fully paid up our RCF facility. We are entering a period of significantly lower CapEx, having completed most foundational investments, which will support improved cash flow and potential shareholder returns.
Q: What are the key drivers for margin improvement in FY25? A: Jakob Sigurdsson, CEO: Margin improvement will be driven by better asset utilization, easing raw material costs, and recovery in medical mix post-destocking. Additionally, our new China facility will reduce its current margin drag as it ramps up production.